AI in healthcare, clinical research, and pharma data science- how real-world data, biobanks, and AI are transforming drug development and patient outcomes. In this episode of Analyzing Healthcare, Roy Bejarano sits down with Angeli Moller, a global pharma data scientist and founder of Sequoia Growth.

Drawing on leadership roles at Bayer and Roche, Angeli shares how data, AI, and clinical research are converging to reshape drug development, healthcare delivery, and global innovation ecosystems.

From the importance of longitudinal data to the realities of biobanks, decentralized care, and global clinical research expansion, this conversation breaks down what actually drives outcomes- not just hype- in healthcare transformation.

What You’ll Learn

• ✅ Why AI fails without clinical and operational foundations
• ✅ How real-world data can reduce drug development timelines
• ✅ The importance of longitudinal datasets in healthcare innovation
• ✅ Why biobanks like UK Biobank create national advantages
• ✅ How data integration across research, manufacturing, and real-world use drives better outcomes
• ✅ Why duplicating analytics infrastructure is inefficient and costly
• ✅ The rise of decentralized care and remote patient monitoring
• ✅ How India and China are emerging as global clinical research leaders
• ✅ Why informed consent and data governance are critical for innovation
• ✅ The evolving role of CROs and federated learning in pharma analytics

Key Timestamps

• (00:00) Introduction to Angeli Moller and her global data leadership
• (03:47) Why AI fails without clinical foundations
• (06:01) What actually drives adoption in healthcare systems
• (07:41) $6B drug development and the role of data
• (13:38) Why “data for data’s sake” fails
• (15:21) Longitudinal data vs. speed in clinical research
• (16:33) UK Biobank, Mayo Clinic, and data advantages
• (18:16) Informed consent and secondary data use
• (24:26) Global competition for clinical research infrastructure
• (30:50) Hospital digitization and operational efficiency
• (34:12) Are we overbuilding analytics in healthcare?
• (37:23) The next 5-year transformation: decentralized care & global research

Key Takeaways

• 💎 AI is only as powerful as the clinical foundation it’s built on
• 💎 Longitudinal data matters more than short-term speed
• 💎 Biobanks and national data infrastructure create competitive advantage
• 💎 Healthcare analytics is becoming overbuilt and inefficient
• 💎 Decentralized care is inevitable—and accelerating
• 💎 Emerging markets are becoming innovation hubs, not just participants
• 💎 Data governance and consent will define the future of healthcare AI
• 💎 Integration across the pharma value chain unlocks exponential value

Resource Links

Guest: Angeli Moller – Founder, Sequoia Growth
Host: Roy Bejarano – CEO & Co-Founder, SCALE Healthcare

Organizations Mentioned:
• Bayer
• Roche
• UK Biobank
• Mayo Clinic

Podcast: Analyzing Healthcare by SCALE Community
SCALE Community: https://www.scale-community.com

Guest Bio

Angeli Moller is a pharma data scientist who worked in leadership positions at Bayer, Roche and Zühlke who two years ago launched a boutique consulting firm, Sequoia Growth. , a consulting firm focused on life sciences analytics and clinical innovation. With leadership experience at Bayer, Roche, and Zürcher, she has led global data integration, clinical analytics, and informatics initiatives across pharma, medtech, and healthcare systems. Her expertise spans clinical trial design, real-world data, AI applications, and global healthcare strategy across Europe, Asia-Pacific, and Latin America.

SEO Keywords

Healthcare AI, Clinical Research, Pharma Data Science, Biobanks, UK Biobank, Mayo Clinic, Drug Development, Real World Data, Healthcare Innovation, AI in Pharma, Clinical Trials, Digital Health, Decentralized Care, Remote Patient Monitoring, Healthcare Strategy, SCALE Healthcare, Roy Bejarano, Angeli Moller, Healthcare Podcast, Global Healthcare Trends